Table 1.
Baseline characteristics of patients in long-term follow-up who remained in remission through end of study
| Patients remaining in remission (n = 13)* | Other patients (n = 13)† | All patients (n = 26) | |
|---|---|---|---|
| Median age (range), y | 52.0 (21-81) | 58.0 (25-82) | 55.5 (21-82) |
| Female, n (%) | 10 (77) | 5 (38) | 15 (58) |
| ECOG performance status, n (%) | |||
| Grade 0 | 6 (46) | 5 (38) | 11 (42) |
| Grade 1 | 5 (38) | 5 (38) | 10 (38) |
| Grade 2 | 2 (15) | 3 (23) | 5 (19) |
| Disease diagnosis | |||
| Systemic ALCL | 9 (69) | 10 (77) | 19 (73) |
| ALK+ | 3 (23) | 0 | 3 (12) |
| ALK− | 6 (46) | 10 (77) | 16 (62) |
| Non-ALCL | 4 (31) | 3 (23) | 7 (27) |
| AITL | 1 (8) | 1 (8) | 2 (8) |
| ATLL | 1 (8) | 1 (8) | 2 (8) |
| PTCL-NOS | 2 (15) | 0 | 2 (8) |
| EATL | 0 | 1 (8) | 1 (4) |
| Median time from diagnosis to first dose (range), d | 29.0 (9-71) | 39.0 (7-109) | 31.5 (7-109) |
| Stage at diagnosis, n (%) | |||
| I | 3 (23) | 0 | 3 (12) |
| II | 2 (15) | 2 (15) | 4 (15) |
| II | 3 (23) | 3 (23) | 6 (23) |
| IV | 5 (38) | 8 (62) | 13 (50) |
| IPI score | |||
| 0-1 | 5 (38) | 3 (23) | 8 (31) |
| 2-3 | 7 (54) | 7 (54) | 14 (54) |
| 4-5 | 1 (8) | 3 (23) | 4 (15) |
| Median SPD in cm2 (range) | 20.6 (4-68) | 17.7 (2-173) | 20.0 (2-173) |
AITL, angioimmunoblastic T-cell lymphoma; ATLL, adult T-cell leukemia/lymphoma; EATL, enteropathy-associated T-cell lymphoma; ECOG, Eastern Cooperative Oncology Group; IPI, International Prognostic Index; PTCL-NOS, peripheral T-cell lymphoma not otherwise specified; SPD, sum of the products of the diameters.
*
Patients with objective response who entered long-term follow-up and remained in remission through end of study with no consolidative stem cell transplant or new anticancer therapy.
†
Patients with objective response who either experienced PD (n = 7) or discontinued the study because of death (n = 5) or withdrawal of consent (n = 1).